Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herzuma plus paclitaxel in HER2-positive recurrent/metastatic urothelial carcinoma
KCT0003543Phase 2Completed
- Sponsor
- Korea University Anam Hospital
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, paclitaxel in transitional cell carcinoma (TCC), sponsored by Korea University Anam Hospital. Started Apr 2019; status: completed.
02
Drugs
trastuzumabpaclitaxel
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on KCT0003543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003543.